Novartis And Eisai End Co-promotion Of COPD Drugs
This article was originally published in PharmAsia News
Executive Summary
Novartis and Eisai ended their co-promotion agreement Dec. 31, 2012 for COPD drugs Onbrez and Seebri sold by Novartis and QVA149 – currently pending marketing approval – the companies announced.